Detalles de la búsqueda
1.
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Cancer Sci
; 115(4): 1273-1282, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38287788
2.
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302.
Int J Clin Oncol
; 26(3): 515-522, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33184754
3.
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
Oncologist
; 25(3): e536-e544, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162801
4.
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Oncologist
; 23(11): 1358-1365, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29934411
5.
Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.
Anticancer Drugs
; 28(5): 565-567, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28225456
6.
Evaluation of rapid measurement of Chlamydia trachomatis and Neisseria gonorrhoeae by using automatic gene analyzer "GENECUBE".
Jpn J Antibiot
; 69(4): 291-298, 2016 Aug.
Artículo
en Inglés, Japonés
| MEDLINE | ID: mdl-30226955
7.
Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
J Thorac Oncol
; 19(2): 337-343, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37943237
8.
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 10(1): 43-51, 2024 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37991747
9.
Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Cancer Rep (Hoboken)
; 7(2): e1981, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212894
10.
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma.
JTO Clin Res Rep
; 5(1): 100613, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38229769
11.
Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.
Thorac Cancer
; 14(27): 2804-2810, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37589158
12.
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Thorac Cancer
; 14(1): 105-107, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36380738
13.
Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.
Thorac Cancer
; 14(31): 3140-3146, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37699787
14.
A retrospective study of the efficacy of combined EGFRTKI plus VEGF inhibitor/cytotoxic therapy vs. EGFRTKI monotherapy for PDL1positive EGFRmutant nonsmall cell lung cancer: North Japan Lung Cancer Study Group 2202.
Oncol Lett
; 26(2): 334, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37427337
15.
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).
Cancer Chemother Pharmacol
; 92(1): 29-37, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37243795
16.
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Thorac Cancer
; 14(2): 168-176, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36408699
17.
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
JTO Clin Res Rep
; 4(12): 100593, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38046378
18.
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
Thorac Cancer
; 13(10): 1471-1478, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35415873
19.
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Clin Cancer Res
; 28(20): 4402-4409, 2022 10 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35980349
20.
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Lancet Respir Med
; 10(1): 72-82, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34454653